Purchase this article with an account.
J. Hernecki, S. Martín, A. Navarro, L. Sararols, R. Paradinas, J. García Arumí; Intraocular Pressure Elevation After Intraocular Triamcinolone Injection in Vitrectomized and Non–Vitrectomized Patients – A Prospective Study . Invest. Ophthalmol. Vis. Sci. 2005;46(13):1459.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To compare intraocular pressure (IOP) elevation following intraocular triamcinolone injection in vitrectomized and non–vitrectomized eyes. Methods: 47 eyes of 47 consecutive patients with macular oedema of different aetiology or subretinal neovascularization in whom intravitreal triamcinolone was administered were studied prospectively. Eyes with pre–existing aqueous dynamics pathology such as glaucoma or uveitis were excluded from the study. 27 eyes were treated with 4 mg of triamcinolone alone while in the remaining 20 eyes 8 mg of triamcinolone was administered at the end of vitrectomy. The retinal surgery was indicated for reasons other than macular oedema, thus the patients were not randomised. Follow–up period was 6 months. Results: There was no statistically significant difference in age, pre–operative visual acuity or IOP between the two groups. Following the triamcinolone injection a significant rise in IOP was observed in both groups (with 42,1%, 38,5%, and 40% in the non–vitrectomy group, and 35,7%, 58,3%, and 16,7% in the vitrectomy group suffering more than 30% rise in IOP from the baseline at 1, 3, and 6 months, respectively, p<0,05). However, the only statistically significant difference between the two groups was at 3 months, with the vitrectomy group IOP being higher (p=0,032). One patint in the vitrectomy group had to undergo filtration surgery due to uncontrolled IOP. Apart from IOP rise, there were no major surgical complications in either group. Conclusions: There appears to be little difference in IOP rise following intravitreal injection of 4 mg triamcinolone in non–vitrectomized eyes and injection of 8 mg triamcinolone following pars plana vitrectomy during six–month follow–up. IOP does not seem to descend to baseline at six months after administration of intravitreal triamcinolone.
This PDF is available to Subscribers Only